Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma

Autor: ML Grossbard, JG Gribben, AS Freedman, JM Lambert, J Kinsella, SN Rabinowe, L Eliseo, JA Taylor, WA Blattler, CL Epstein

Publikováno v: Blood. 81(9)

Anti-B-blocked ricin (anti-B4-bR) combines the specificity of the anti- B4 (CD19) monoclonal antibody with the protein toxin “blocked ricin.” In blocked ricin, affinity ligands are attached to the ricin B-chain to attenuate its lectin binding cap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c16e7155ef3637447620bf39e7884c3f
https://pubmed.ncbi.nlm.nih.gov/8481509

Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.

Autor: Grossbard ML; Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, USA., Fidias P, Kinsella J, O'Toole J, Lambert JM, Blattler WA, Esseltine D, Braman G, Nadler LM, Anderson KC

Publikováno v: British journal of haematology [Br J Haematol] 1998 Jul; Vol. 102 (2), pp. 509-15.

Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures.

Autor: La Russa VF; Department of Hematology, Walter Reed Army Institute of Research, Washington, DC 20307-5100., Griffin JD, Kessler SW, Cutting MA, Knight RD, Blattler WA, Lambert JM, Wright DG

Publikováno v: Experimental hematology [Exp Hematol] 1992 May; Vol. 20 (4), pp. 442-8.

Resting human peripheral blood lymphocytes can be activated to cytolytic function by antibodies to CD3 in the absence of exogenous interleukin-2.

Autor: Scott CF Jr; Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115., Lambert JM, Bolender S, Blattler WA

Publikováno v: Cellular immunology [Cell Immunol] 1988 Jul; Vol. 114 (2), pp. 370-84.